Molecular regulation of immune complex disease
Molecular regulation of immune complex disease
批准号:
6993611
负责人:
JOERG KOEHL
金额:
$36.37万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-12-15 至 2009-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Autoimmune diseases afflict 14-22 million people in the U.S. alone. Immune complexes (IC) are integral to the pathogenesis of several autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. IC activates the complement system and thus interacts both with receptors for Fc of immunoglobulin G (Fc(R) and a variety of complement receptors. FcgammaR comprise two classes of receptors: activating and inhibitory receptors, the balance of which defines the effector response after receptor ligation. The prototypic experimental model of soluble IC disease is the Arthus reaction, characterized by edema, hemorrhage and neutrophil infiltration.
Activating FcgammaR and the complement cleavage product C5a receptor (C5aR) are essential to the pathology in the Arthus model. Further, there is clear evidence of cross-regulation between FcgammaR and C5aR induced signaling pathways. C5aR signaling alters the balance between activating and inhibitory FcgammaR. In turn, FcgammaR signaling can modulate C5aR-driven effector functions. Engagement of activating FcgammaR and C5aR induces the release of the CXC chemokines KC and MIP- 2 by resident peritoneal mast cells and macrophages, which play an important role in neutrophil trafficking in this model. Of note, signaling through inhibitory FcgammaR inhibits neutrophil chemotaxis towards KC and C5a, suggesting modulation of conserved signaling pathways downstream of the receptors for these chemoattractants.
The long-term goal of this research is to define the molecular mechanisms that regulate IC-mediated autoimmune processes. The central hypothesis of the studies proposed here is that IC mediated inflammation is regulated at two levels by bidirectional interactions between chemoattractant receptors and Fc(R, including: (1) modulation of the effector functions of activating Fc(R through engagement of chemoattractant receptors; (2) regulation of chemoattractant receptor effector functions through engagement of inhibitory Fc(R. We aim to: (1) define the specific roles of chemoattractant receptors and Fc(R signaling by resident and infiltrating cells in the regulation of immune complex-mediated inflammatory responses; (2) determine the mechanisms by which chemoattractant receptor signaling regulates Fc(R function; and (3) characterize the mechanisms by which inhibitory FcgammaR signaling regulates chemoattractant receptor function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular regulation of immune complex disease
-
批准号:6866069
-
项目类别:
-
资助金额:$27.94万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Complement in Allergic Asthma: The role of C3a and C5a
-
批准号:6890426
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Complement in Allergic Asthma: The role of C3a and C5a
-
批准号:7407389
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Complement in Allergic Asthma: The role of C3a and C5a
-
批准号:6823173
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Molecular regulation of immune complex disease
-
批准号:7533994
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Molecular regulation of immune complex disease
-
批准号:7149183
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Molecular regulation of immune complex disease
-
批准号:7322501
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Molecular regulation of immune complex disease
-
批准号:6760681
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Complement in Allergic Asthma: The role of C3a and C5a
-
批准号:7233264
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
Complement in Allergic Asthma: The role of C3a and C5a
-
批准号:7052073
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2004
-
负责人:JOERG KOEHL
-
依托单位:
国内基金
海外基金
登录
查看更多内容
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
-
批准号:82371634
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵福军
-
依托单位:
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
-
批准号:82371651
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵栋
-
依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
-
批准号:82370798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王晓
-
依托单位:
精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
-
批准号:82371770
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:宁铂涛
-
依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
-
批准号:82371801
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:周海波
-
依托单位:
TIPE2调控巨噬细胞M2极化改善睑板腺功能障碍的作用机制研究
-
批准号:82371028
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵慧
-
依托单位:
亚低温调控颅脑创伤急性期神经干细胞Mpc2/Lactate/H3K9lac通路促进神经修复的研究
-
批准号:82371379
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:冯军峰
-
依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
-
批准号:82372275
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘耀宝
-
依托单位:
α-酮戊二酸调控ACMSD介导犬尿氨酸通路代谢重编程在年龄相关性听力损失中的作用及机制研究
-
批准号:82371150
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:侯书乐
-
依托单位:
mPFC-VTA-NAc多巴胺能投射调控丙泊酚麻醉—觉醒的机制研究
-
批准号:82371284
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:许涛
-
依托单位: